Identification

Name
Olanzapine
Accession Number
DB00334  (APRD00138)
Type
Small Molecule
Groups
Approved, Investigational
Description

Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.

Structure
Thumb
Synonyms
  • 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
  • Olanzapin
  • Olanzapina
  • Olanzapine
  • Olanzapinum
External IDs
LY 170053 / LY-170053 / UNII-X7S6Q4MHCB
Product Ingredients
IngredientUNIICASInChI Key
Olanzapine hydrochloride0Q8K2L0MC3783334-36-1MFURKUWVJOJUHP-UHFFFAOYSA-N
Olanzapine pamoateX7S6Q4MHCB221373-18-8ZIMCQJVMPKQQPB-UHFFFAOYSA-N
Olanzapine tartrate0KNI3MFH5F491828-16-1NFEUHAIRXOEOTJ-LREBCSMRSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-olanzapine ODTTablet, orally disintegrating15 mgOralAbbott2014-12-032015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegrating5 mgOralBgp Pharma Ulc2014-09-172015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegrating10 mgOralAbbott2014-09-172015-12-31Canada
Accel-olanzapineTablet15 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet7.5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet2.5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet10 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet20 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-olanzapineTablet5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Act OlanzapineTablet20 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olanzapineTablet7.5 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapineTablet20.0 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapineTablet2.5 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapineTablet10.0 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapineTablet5.0 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapineTablet15.0 mgOralApotex Corporation2009-10-09Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating5 mgOralApotex Corporation2011-11-16Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating20 mgOralApotex Corporation2011-08-08Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating10 mgOralApotex Corporation2011-08-08Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating15 mgOralApotex Corporation2011-08-08Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated2.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated15 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated2.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated7.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated15 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
International/Other Brands
Aedon (G.L. Pharma) / Amulsin (Sanitas) / Apisco (LKM) / Apsico (LKM) / Arkolamyl (Mylan) / Caprilon (Lavipharm) / CO Olanzapine (Cobalt) / Deprex (Square) / Dominazol (Stein) / Dopin (Daksh) / Egolanza (EGIS) / Elynza (Elynza) / Frenial (Biogen) / Jolyon-MD (Lupin) / Kozylex (Quisisana) / Lanopin (Molekule) / Lanzapin (Biogened) / Lanzep (Renata) / Lapenza (Smart Intermed) / Lapozan (Medochemie) / Lazapix (Portfarma) / Zyprexa
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine Hydrochloride (50 mg/1)CapsuleOralPar Pharmaceutical2012-11-28Not applicableUs
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineOlanzapine (3 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs
Olanzapine and FluoxetineOlanzapine (3 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs00093 5506 56 nlmimage10 1e270f18
Olanzapine and FluoxetineOlanzapine (3 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralTeva2013-04-10Not applicableUs00093 5503 56 nlmimage10 a8365432
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine Hydrochloride (50 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineOlanzapine (6 mg/1) + Fluoxetine Hydrochloride (50 mg/1)CapsuleOralPar Pharmaceutical2012-11-28Not applicableUs
Olanzapine and FluoxetineOlanzapine (12 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralTeva2012-06-19Not applicableUs
Olanzapine and FluoxetineOlanzapine (3 mg/1) + Fluoxetine Hydrochloride (25 mg/1)CapsuleOralPar Pharmaceutical2012-11-28Not applicableUs49884 0277 11 nlmimage10 c53be2ef
Categories
UNII
N7U69T4SZR
CAS number
132539-06-1
Weight
Average: 312.432
Monoisotopic: 312.14086735
Chemical Formula
C17H20N4S
InChI Key
KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
IUPAC Name
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2

Pharmacology

Indication

For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.

Structured Indications
Pharmacodynamics

Olanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.

Mechanism of action

Olanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
agonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(1B) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
U5-hydroxytryptamine receptor 1E
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
U5-hydroxytryptamine receptor 2B
antagonist
Human
U5-hydroxytryptamine receptor 5A
antagonist
Human
UD(1) dopamine receptor
antagonist
Human
UHistamine H2 receptor
antagonist
Human
UHistamine H4 receptor
antagonist
Human
UGABA-A receptor (anion channel)Not AvailableHuman
UBeta adrenergic receptorNot AvailableHuman
UD(2L) dopamine receptorNot AvailableHuman
UD(2S) dopamine receptorNot AvailableHuman
Absorption

Well absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.

Volume of distribution
  • 1000 L
Protein binding

93%

Metabolism

Hepatic

Route of elimination

It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.

Half life

21 to 54 hours

Clearance
  • 12 to 47 L/h
Toxicity

Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
5-hydroxytryptamine receptor 1A---(C;C)CC Allele (homozygous)Effect Directly StudiedThe presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with olanzapine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Olanzapine.Investigational
2,5-Dimethoxy-4-ethylamphetamineOlanzapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineOlanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Olanzapine.Experimental
AbirateroneThe serum concentration of Olanzapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Olanzapine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine.Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine.Experimental, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Olanzapine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine.Approved, Vet Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Olanzapine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Olanzapine.Approved
AmiodaroneOlanzapine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amperozide.Experimental
AmphetamineOlanzapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideOlanzapine may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherOlanzapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine.Approved
AsenapineOlanzapine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Olanzapine.Approved, Investigational
AtomoxetineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Azaperone.Investigational, Vet Approved
AzelastineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinOlanzapine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Olanzapine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital.Illicit
BedaquilineOlanzapine may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Olanzapine.Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Olanzapine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benzocaine.Approved
BenzphetamineOlanzapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Olanzapine can be decreased when combined with Betaxolol.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine.Investigational
BMS-906024The risk or severity of adverse effects can be increased when Olanzapine is combined with BMS-906024.Investigational
BortezomibThe metabolism of Olanzapine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Olanzapine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Olanzapine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine.Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bupivacaine.Approved, Investigational
BuprenorphineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Olanzapine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Olanzapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olanzapine.Approved
CaffeineThe metabolism of Olanzapine can be decreased when combined with Caffeine.Approved
CamazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Camazepam.Approved, Illicit
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Olanzapine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Olanzapine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Olanzapine.Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine.Experimental
CE-326597The risk or severity of adverse effects can be increased when Olanzapine is combined with CE-326597.Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Olanzapine.Approved
CefpodoximeOlanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeOlanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibThe metabolism of Olanzapine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibOlanzapine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Olanzapine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine.Approved
ChloroquineOlanzapine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine.Approved
ChlorphentermineOlanzapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Olanzapine.Experimental
ChlorpromazineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Olanzapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Olanzapine.Approved
CimetidineThe metabolism of Olanzapine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Olanzapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinOlanzapine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideOlanzapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOlanzapine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinOlanzapine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Olanzapine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Olanzapine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Olanzapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineOlanzapine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Olanzapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Olanzapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine.Approved, Illicit
CrizotinibOlanzapine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Olanzapine.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Olanzapine.Investigational
DarifenacinThe metabolism of Olanzapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Olanzapine can be increased when it is combined with Darunavir.Approved
DasatinibOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Olanzapine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Delorazepam.Approved, Illicit, Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Olanzapine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desflurane.Approved
DesipramineThe metabolism of Olanzapine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Olanzapine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateOlanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineOlanzapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Olanzapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diethyl ether.Experimental
DiethylpropionOlanzapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Olanzapine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Olanzapine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Olanzapine.Experimental
DihydroetorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Olanzapine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate.Approved, Illicit
DisopyramideOlanzapine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dixyrazine.Experimental
DofetilideOlanzapine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronOlanzapine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneOlanzapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Olanzapine can be decreased when combined with Dosulepin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Illicit
DronedaroneOlanzapine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Olanzapine.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Olanzapine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Olanzapine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.Approved, Investigational
EliglustatOlanzapine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
ErythromycinOlanzapine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramOlanzapine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone.Approved
EthanolOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Olanzapine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Olanzapine.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseOlanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateOlanzapine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateOlanzapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fexofenadine.Approved
FlecainideOlanzapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fludiazepam.Approved, Illicit
FlumazenilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flumazenil.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineOlanzapine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolOlanzapine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Olanzapine.Approved
FluvoxamineThe metabolism of Olanzapine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Olanzapine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olanzapine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidOlanzapine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Olanzapine.Approved, Investigational
GemifloxacinOlanzapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineOlanzapine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Olanzapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine.Approved
GoserelinOlanzapine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronOlanzapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Olanzapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolOlanzapine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Olanzapine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Olanzapine.Experimental
HydrocodoneOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine.Approved, Illicit
HydroxyamphetamineOlanzapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
IbutilideOlanzapine may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneOlanzapine may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe metabolism of Olanzapine can be decreased when combined with Imipramine.Approved
IndalpineIndalpine may increase the serotonergic activities of Olanzapine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Olanzapine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Indiplon.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Olanzapine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Olanzapine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.Approved
Iofetamine I-123Olanzapine may decrease the stimulatory activities of Iofetamine I-123.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Olanzapine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olanzapine.Withdrawn
IronOlanzapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranOlanzapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateOlanzapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olanzapine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Olanzapine can be decreased when combined with Isoniazid.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
LamotrigineLamotrigine may increase the sedative activities of Olanzapine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Olanzapine.Approved
LenvatinibOlanzapine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideOlanzapine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Olanzapine.Approved
LevofloxacinOlanzapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Olanzapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol.Approved
LidocaineThe metabolism of Olanzapine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine.Approved
LisdexamfetamineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Olanzapine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Olanzapine.Approved
LobeglitazoneThe metabolism of Olanzapine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lofentanil.Illicit
LopinavirOlanzapine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lorazepam.Approved
LorcaserinThe metabolism of Olanzapine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lormetazepam.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Olanzapine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Loxapine.Approved
LumacaftorThe serum concentration of Olanzapine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineOlanzapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Olanzapine.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
ManidipineThe metabolism of Olanzapine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Olanzapine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Olanzapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Melperone.Approved, Investigational
MephedroneOlanzapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineOlanzapine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meptazinol.Experimental
MequitazineOlanzapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Olanzapine.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.Approved
MethadoneOlanzapine may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineOlanzapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methohexital.Approved
MethotrimeprazineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineOlanzapine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Olanzapine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Olanzapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Olanzapine.Approved, Investigational
MetyrosineOlanzapine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Olanzapine.Experimental
MexiletineThe metabolism of Olanzapine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.Approved, Illicit
MidomafetamineOlanzapine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Olanzapine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Olanzapine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Olanzapine.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Olanzapine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Olanzapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
MirabegronThe metabolism of Olanzapine can be decreased when combined with Mirabegron.Approved
MirtazapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
MMDAOlanzapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Olanzapine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Olanzapine.Approved, Investigational
MoxifloxacinOlanzapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Olanzapine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine.Approved
NetazepideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Netazepide.Investigational
NevirapineThe metabolism of Olanzapine can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Olanzapine.Withdrawn
NicardipineThe metabolism of Olanzapine can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine.Approved, Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Olanzapine.Withdrawn
OfloxacinOlanzapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Olopatadine.Approved
OndansetronOlanzapine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Opium.Approved, Illicit
OrphenadrineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Olanzapine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneOlanzapine may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Olanzapine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Olanzapine.Approved
ParoxetineThe metabolism of Olanzapine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Olanzapine.Approved
Peginterferon alfa-2bThe serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Penfluridol.Experimental
PentamidineOlanzapine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine.Investigational
PerflutrenOlanzapine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Olanzapine.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olanzapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine.Approved
PF-477736The risk or severity of adverse effects can be increased when Olanzapine is combined with PF-477736.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Olanzapine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Olanzapine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Olanzapine.Withdrawn
PhentermineOlanzapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenytoin.Approved, Vet Approved
PimozideOlanzapine may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pirenzepine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Olanzapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olanzapine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Olanzapine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Olanzapine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Olanzapine.Approved, Investigational, Vet Approved
PramipexoleOlanzapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Olanzapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Olanzapine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olanzapine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prilocaine.Approved
PrimaquineOlanzapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Primidone.Approved, Vet Approved
ProcainamideOlanzapine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.Approved, Vet Approved
PromazineOlanzapine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine.Approved
PropafenoneOlanzapine may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Olanzapine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Olanzapine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Olanzapine is combined with PSD502.Investigational
PseudoephedrineOlanzapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Quazepam.Approved, Illicit
QuetiapineOlanzapine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Olanzapine.Approved
QuinidineOlanzapine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineOlanzapine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Olanzapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olanzapine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Olanzapine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ritanserin.Investigational
RitobegronOlanzapine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine.Approved
RolapitantThe metabolism of Olanzapine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Romifidine.Vet Approved
RopiniroleOlanzapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Olanzapine.Approved
RotigotineOlanzapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olanzapine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Olanzapine.Withdrawn
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Olanzapine.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Olanzapine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe metabolism of Olanzapine can be decreased when combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Olanzapine.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Olanzapine.Approved, Investigational
SJG-136The risk or severity of adverse effects can be increased when Olanzapine is combined with SJG-136.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Olanzapine.Investigational
SotalolOlanzapine may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe metabolism of Olanzapine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleOlanzapine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine.Approved, Investigational
SuvorexantOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Olanzapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine.Approved
TelavancinOlanzapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinOlanzapine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.Approved
Tenofovir disoproxilThe metabolism of Olanzapine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Olanzapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Olanzapine.Experimental
TeriflunomideThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrodotoxin.Investigational
ThalidomideOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Olanzapine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Olanzapine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Olanzapine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Olanzapine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Olanzapine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Olanzapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tilidine.Experimental
TipranavirThe metabolism of Olanzapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Olanzapine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Olanzapine.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Olanzapine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Olanzapine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Topiramate.Approved
ToremifeneOlanzapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Olanzapine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olanzapine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olanzapine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Olanzapine.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Olanzapine.Approved, Experimental
Valproic AcidThe serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid.Approved, Investigational
VandetanibOlanzapine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Olanzapine.Approved, Investigational
VemurafenibThe serum concentration of Olanzapine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Olanzapine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the serotonergic activities of Olanzapine.Withdrawn
ZiprasidoneOlanzapine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine.Approved, Investigational
ZolpidemOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Olanzapine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolOlanzapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, "Intermediates and process for preparing olanzapine." U.S. Patent US6020487, issued September, 1996.

US6020487
General References
  1. de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. [PubMed:15322727]
  2. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. [PubMed:16139813]
  3. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. [PubMed:16415705]
  4. Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. [PubMed:12752037]
  5. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. [PubMed:12648731]
External Links
Human Metabolome Database
HMDB05012
KEGG Drug
D00454
KEGG Compound
C07322
PubChem Compound
4585
PubChem Substance
46507666
ChemSpider
10442212
BindingDB
35254
ChEBI
7735
ChEMBL
CHEMBL715
Therapeutic Targets Database
DAP000022
PharmGKB
PA450688
IUPHAR
47
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Olanzapine
ATC Codes
N05AH03 — Olanzapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (251 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceNormal Non-fluency1
1CompletedTreatmentCancer, Advanced / Obese experiencing rapid weight loss1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting2
1CompletedTreatmentFed2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentMood Disorders With Psychotic Features / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders1
1RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentSchizophrenic Disorders1
1TerminatedNot AvailableHealthy Volunteers1
1, 2CompletedTreatmentSchizophrenic Disorders3
1, 2CompletedTreatmentSubjects Had Unipolar, Non-psychotic Major Depression1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
2CompletedSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcohol Use Disorder (AUD) / Schizophrenic Disorders1
2CompletedTreatmentAnorexia Nervosa (AN)1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentEating Disorders1
2CompletedTreatmentSchizophrenic Disorders15
2Not Yet RecruitingTreatmentCancers1
2RecruitingOtherAdverse Effect of Other Antipsychotics and Neuroleptics / Insulin Resistance1
2RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
2RecruitingSupportive CareHematopoietic System--Cancer / Nausea / Vomiting in Infants and/or Children1
2RecruitingTreatmentSchizophrenic Disorders1
2RecruitingTreatmentTreatment-resistant Schizophrenia1
2TerminatedSupportive CareVomiting1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
2Unknown StatusSupportive CareNausea / Vomiting1
2Unknown StatusSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
2WithdrawnTreatmentSchizophrenic Disorders1
2, 3CompletedTreatmentAutism, Early Infantile1
2, 3RecruitingTreatmentCancer, Advanced1
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3Unknown StatusTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2, 3WithdrawnTreatmentDiabetes1
3Active Not RecruitingSupportive CareHematopoietic/Lymphoid Cancer / Nausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedPreventionSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedPreventionWeight gain therapy1
3CompletedTreatmentAcute Agitation / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentAcute Schizophrenia1
3CompletedTreatmentAlcohol Dependence1
3CompletedTreatmentBipolar Disorder (BD)8
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar Disorder I or II1
3CompletedTreatmentBipolar I Disorder2
3CompletedTreatmentBorderline Personality Disorder (BPD)2
3CompletedTreatmentDepression, Bipolar1
3CompletedTreatmentDevelopmental Delay Disorders / Mental Retardation1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentMajor Depressive Disorder With Psychotic Features1
3CompletedTreatmentManic or Mixed Episode Associated With Bipolar I Disorder1
3CompletedTreatmentMental Health / Psychiatric Disorder NOS / Psychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentPathological Gambling1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders3
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders24
3CompletedTreatmentTreatment Resistant Depression (TRD)1
3Not Yet RecruitingSupportive CareNausea / Vomiting1
3Not Yet RecruitingSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
3RecruitingPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
3RecruitingSupportive CareComplications of Bone Marrow Transplant / Neoplasms, Hematologic1
3RecruitingTreatmentBipolar I Disorder / Schizophrenic Disorders / Schizophreniform Disorders1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentHuntington's Disease (HD)1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3RecruitingTreatmentSchizophrenic Disorders2
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentEating Disorder1
3TerminatedTreatmentNausea / Neoplasms1
3TerminatedTreatmentTherapy-Resistant Depression1
3TerminatedTreatmentTreatment Resistant Depression (TRD)1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentRelapse Rate of a Major Depressive Episode / Safety of Olanzapine in Subjects With Major Depression1
3WithdrawnTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentPsychotic Depression1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedBasic ScienceDiabetes2
4CompletedBasic ScienceDiabetes / Schizophrenic Disorders1
4CompletedBasic ScienceSchizophrenic Disorders / Sleep1
4CompletedDiagnosticMajor Depressive Disorder (MDD)1
4CompletedPreventionBipolar Disorder (BD)1
4CompletedPreventionSchizophrenic Disorders2
4CompletedTreatmentAdhd / Aggressive Behavior / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnorexia Nervosa (AN)1
4CompletedTreatmentAnxiety Disorders / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)10
4CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar1
4CompletedTreatmentBipolar Disorder (BD) / Depression / Depressive Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar I Disorder1
4CompletedTreatmentBipolar I Disorder / Schizophrenic Disorders1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentDementias1
4CompletedTreatmentDepression, Bipolar3
4CompletedTreatmentDepression / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentDiabetes Mellitus (DM) / Schizophrenic Disorders1
4CompletedTreatmentDiabetes / Hyperglycemias / Metabolic Syndromes / Schizophrenic Disorders1
4CompletedTreatmentEating Disorders1
4CompletedTreatmentEmergency Psychiatric / Psychiatric Disorders / Psychomotor Agitation / Tranquilizers1
4CompletedTreatmentExtrapyramidal Syndrome / Schizophrenic Disorders1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentNeurocognitive Function / Tardive Dyskinesia1
4CompletedTreatmentNeuroleptic-Induced Tardive Dyskinesia1
4CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenia, Childhood / Schizophrenic Disorders1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders7
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder2
4CompletedTreatmentSchizophrenic Disorders26
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentTrichotillomania1
4CompletedTreatmentWeight gain therapy1
4RecruitingBasic ScienceHealthy Volunteers1
4RecruitingTreatmentAcute Agitation, Behavioural Emergency1
4RecruitingTreatmentAcute Agitation / Behavioural Emergency1
4RecruitingTreatmentBipolar Disorder (BD)3
4RecruitingTreatmentBipolar Disorder (BD) / Schizoaffective Disorders1
4RecruitingTreatmentEarly-onset Schizophrenia1
4RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4RecruitingTreatmentSchizophrenic Disorders2
4TerminatedTreatmentAcute Mania / Bipolar Disorder, Manic1
4TerminatedTreatmentBipolar Disorder (BD)2
4TerminatedTreatmentSchizophrenic Disorders2
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnPreventionSchizoaffective Disorders / Schizophrenic Disorders1
4WithdrawnPreventionSchizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentBipolar Disorder (BD) / BMI >30 kg/m2 / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableDyslipidemias / Insulin Resistance1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM) / Insulin Resistance1
Not AvailableCompletedBasic ScienceDiabetes / Insulin Resistance / Schizophrenic Disorders1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceSchizophrenic Disorders1
Not AvailableCompletedPreventionDelirium1
Not AvailableCompletedPreventionHyperglycemias / Hyperlipidemias1
Not AvailableCompletedPreventionWeight gain therapy1
Not AvailableCompletedScreeningBMI >30 kg/m2 / Diabetes / Metabolic Syndromes1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAnorexia Nervosa (AN)1
Not AvailableCompletedTreatmentAnorexia Nervosa (AN) / Bulimia Nervosa (BN)1
Not AvailableCompletedTreatmentBorderline Personality Disorder (BPD)1
Not AvailableCompletedTreatmentCancer, Advanced1
Not AvailableCompletedTreatmentCancer, Advanced / Delirium1
Not AvailableCompletedTreatmentDelusional Disorder / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentPsychomotor Agitation1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders2
Not AvailableCompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus2
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAdhd / Anorexia Nervosa (AN) / Depression1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableNausea / Vomiting1
Not AvailableRecruitingNot AvailablePsychomotor Agitation1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders2
Not AvailableRecruitingTreatmentHeadaches1
Not AvailableRecruitingTreatmentIdiopathic Gastroparesis1
Not AvailableRecruitingTreatmentSchizophrenic Disorders2
Not AvailableRecruitingTreatmentSubstance Withdrawal Syndrome1
Not AvailableTerminatedTreatmentAcute Agitation / Delirium1
Not AvailableTerminatedTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS1
Not AvailableTerminatedTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusSupportive CareSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableWithdrawnSupportive CareHematopoietic/Lymphoid Cancer / Pain / Unspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
TabletOral10.0 mg
TabletOral15.0 mg
TabletOral20.0 mg
TabletOral5.0 mg
Injection, powder, for solutionIntramuscular10 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular10 mg/2mL
TabletOral2.5 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral20 mg/1
Tablet, orally disintegratingOral5 mg/1
CapsuleOral
Tablet, film coatedOral10 mg
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral7.5 mg
Tablet, coatedOral10 mg
Tablet, coatedOral15 mg
Tablet, coatedOral2.5 mg
Tablet, coatedOral5 mg
Tablet, coatedOral7.5 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral20 mg
Tablet, orally disintegratingOral7.5 mg
TabletOral2.5 mg
TabletOral7.5 mg
Injection, powder, for suspension, extended releaseIntramuscular210 mg
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular405 mg
Injection, powder, for solutionIntramuscular10 mg
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Tablet, coatedOral20 mg
TabletOral10 mg
TabletOral5 mg
TabletOral15 mg
TabletOral20 mg
Powder, for solutionIntramuscular10 mg
KitIntramuscular
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral20 mg
Tablet, orally disintegratingOral5 mg
Prices
Unit descriptionCostUnit
Zyprexa relprevv 405 mg vial1287.9USD vial
Zyprexa relprevv 300 mg vial954.0USD vial
Zyprexa relprevv 210 mg vial667.8USD vial
ZyPREXA Zydis 30 10 mg Dispersible Tablet Box562.35USD box
ZyPREXA Zydis 30 5 mg Dispersible Tablet Box385.63USD box
Zyprexa 10 mg vial35.69USD vial
Zyprexa zydis 20 mg tablet34.87USD tablet
Zyprexa 20 mg tablet34.37USD tablet
Zyprexa zydis 15 mg tablet26.45USD tablet
Zyprexa 15 mg tablet21.14USD tablet
Symbyax 12-25 mg capsule20.62USD capsule
Symbyax 12-50 mg capsule20.62USD capsule
Zyprexa zydis 10 mg tablet18.02USD tablet
Symbyax 6-50 mg capsule14.56USD capsule
Zyprexa 10 mg tablet14.09USD tablet
Symbyax 6-25 mg capsule13.69USD capsule
Zyprexa zydis 5 mg tablet12.36USD tablet
Zyprexa 7.5 mg tablet11.23USD tablet
Symbyax 3-25 mg capsule10.01USD capsule
Zyprexa 5 mg tablet8.92USD tablet
Zyprexa Zydis 10 mg Disintegrating Tablet7.86USD tablet
Zyprexa 2.5 mg tablet7.1USD tablet
Apo-Olanzapine 15 mg Tablet6.64USD tablet
Co Olanzapine 15 mg Tablet6.64USD tablet
Novo-Olanzapine 15 mg Tablet6.64USD tablet
Pms-Olanzapine 15 mg Tablet6.64USD tablet
Apo-Olanzapine 10 mg Tablet4.43USD tablet
Co Olanzapine 10 mg Tablet4.43USD tablet
Novo-Olanzapine 10 mg Tablet4.43USD tablet
Pms-Olanzapine 10 mg Tablet4.43USD tablet
Zyprexa Zydis 5 mg Disintegrating Tablet3.93USD tablet
Co Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Novo-Olanzapine Od 10 mg Disintegrating Tablet3.54USD tablet
Pms-Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Sandoz Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Apo-Olanzapine 7.5 mg Tablet3.32USD tablet
Co Olanzapine 7.5 mg Tablet3.32USD tablet
Novo-Olanzapine 7.5 mg Tablet3.32USD tablet
Pms-Olanzapine 7.5 mg Tablet3.32USD tablet
Apo-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine 5 mg Tablet2.21USD tablet
Novo-Olanzapine 5 mg Tablet2.21USD tablet
Pms-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Novo-Olanzapine Od 5 mg Disintegrating Tablet1.77USD tablet
Pms-Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Sandoz Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Apo-Olanzapine 2.5 mg Tablet1.11USD tablet
Co Olanzapine 2.5 mg Tablet1.11USD tablet
Novo-Olanzapine 2.5 mg Tablet1.11USD tablet
Pms-Olanzapine 2.5 mg Tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6251895No1998-03-232018-03-23Us
US5229382No1994-04-232011-04-23Us
CA2216372No2007-11-202016-03-22Canada
CA2041113No1998-07-142011-04-24Canada
US6960577No1997-11-012017-11-01Us
US5945416No1997-03-242017-03-24Us
US6169084No1998-09-302018-09-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)195 °CNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0942 mg/mLALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m3·mol-1ChemAxon
Polarizability35.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9652
Caco-2 permeable+0.5993
P-glycoprotein substrateSubstrate0.8524
P-glycoprotein inhibitor IInhibitor0.6888
P-glycoprotein inhibitor IIInhibitor0.7204
Renal organic cation transporterInhibitor0.7715
CYP450 2C9 substrateNon-substrate0.7493
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateInhibitor0.6454
CYP450 2C9 inhibitorNon-inhibitor0.6914
CYP450 2D6 inhibitorInhibitor0.608
CYP450 2C19 inhibitorInhibitor0.572
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.7569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0009000000-256a6e976b00468fe839
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0049000000-83ee647255e8d18f2b5c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-81810b42dccae4ee9ab6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0bt9-0490000000-8994262c6a309d663713
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ot-0950000000-ceb0ca01cefbd1da57d7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0149000000-e74851873e2fbaa6c182
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dj-0940000000-1103f40c5bb833e12903
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dj-0940000000-37cb2e8fb99c38b097b8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0149000000-338b982664cf3019be13
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2790000000-bdc5a34b08715b752eef

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
Not Available
Direct Parent
Benzodiazepines
Alternative Parents
Thienodiazepines / 2,3,5-trisubstituted thiophenes / N-methylpiperazines / N-arylated-2-aminothiophenes / 1,4-diazepines / Imidolactams / Benzenoids / Heteroaromatic compounds / Trialkylamines / Secondary amines
show 5 more
Substituents
Benzodiazepine / Thieno-para-diazepine / 2,3,5-trisubstituted thiophene / Para-diazepine / N-methylpiperazine / N-alkylpiperazine / N-arylated-2-aminothiophene / 1,4-diazinane / Piperazine / 2-aminothiophene
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, N-methylpiperazine, benzodiazepine (CHEBI:7735)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903]
  2. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F: Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep;18(3):355-65. [PubMed:15358979]
  3. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ: Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005 Apr;66(4):450-4. [PubMed:15816787]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601]
  5. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, Brea J, Caruncho HJ, Isabel Cadavid M, Castro M, Isabel Loza M: Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology. 2006 Sep;51(4):923-32. Epub 2006 Aug 14. [PubMed:16905159]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800]
  4. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T: In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8. [PubMed:17092971]
  5. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci. 2006 Oct;24(7):2075-83. [PubMed:17067304]
  6. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006 Mar;163(3):529-31. [PubMed:16513877]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
3. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Details
4. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Details
5. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
6. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R: The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun;31(6):1310-7. [PubMed:16237394]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5. [PubMed:16336943]
  3. Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11. [PubMed:17624999]
  4. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396]
  6. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163]
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
15. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3. [PubMed:15729086]
  3. Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9- diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1. [PubMed:16141369]
  4. Altschuler EL, Kast RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005;65(1):65-7. [PubMed:15893120]
  5. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  3. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  4. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR5A
Uniprot ID
P47898
Uniprot Name
5-hydroxytryptamine receptor 5A
Molecular Weight
40254.69 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  3. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agoni...
Gene Name
HRH4
Uniprot ID
Q9H3N8
Uniprot Name
Histamine H4 receptor
Molecular Weight
44495.375 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531]
33. D(2L) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
34. D(2S) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34